Alto Neuroscience (ANRO) Stock Price, News & Analysis

Company Overview

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.

Key Stats

• Today's Range: $23.65 to $24.91
• 50-Day Range: $18.93 to $27.66
• 52-Week Range: $2.15 to $28.44
• Volume: 52,020 shs
• Average Volume: 269,271 shs
• Market Capitalization: $782.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.13
• Consensus Rating: Moderate Buy

Alto Neuroscience Stock Analysis - MarketRank™

Alto Neuroscience scored higher than 37% of companies evaluated by MarketBeat, and ranked 647th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alto Neuroscience has a consensus price target of $35.13, representing about 43.5% upside from its current price of $24.48.

Amount of Analyst Coverage

Alto Neuroscience has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.47) to ($3.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alto Neuroscience is -11.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alto Neuroscience is -11.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alto Neuroscience has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.73% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 5.37.

Change versus previous month

Short interest in Alto Neuroscience has recently increased by 6.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alto Neuroscience does not currently pay a dividend.

Dividend Growth

Alto Neuroscience does not have a long track record of dividend growth.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.25

News Sentiment

Alto Neuroscience has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Alto Neuroscience this week, compared to 7 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.25% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Alto Neuroscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 3/16/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ANRO
• Previous Symbol: NYSE:ANRO
• CIK: 1999480
• Web: www.altoneuroscience.com
• Phone: (650) 200-0412
• Fax: N/A
• Employees: N/A
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Alto Neuroscience: $35.13
• High Price Target: $50.00
• Low Price Target: $21.00
• Potential Upside/Downside: +43.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.64%
• Return on Assets: -37.83%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 15.69
• Quick Ratio: 15.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.87 per share
• Price / Book: 5.04

Miscellaneous

• Outstanding Shares: 31,946,000
• Free Float: 28,352,000
• Market Cap: $783.64 million
• Optionable: N/A
• Beta: 1.62